There is no single best medicine for bladder control. The right choice depends on the type of incontinence you have, your age, other health conditions, and how well you tolerate side effects. For the most common type of bladder control problem, overactive bladder, two main drug classes are used: antimuscarinics (also called anticholinergics) and beta-3 agonists. Both are effective, but they work differently and carry different risks.
Two Main Drug Classes for Overactive Bladder
Overactive bladder happens when the muscle surrounding your bladder contracts too often or at the wrong times, creating sudden urgency, frequent trips to the bathroom, and sometimes leaking before you get there. Medications target this muscle in two distinct ways.
Antimuscarinics block the chemical signal that tells the bladder muscle to squeeze. They’ve been the go-to treatment for decades and include oxybutynin, tolterodine, solifenacin, darifenacin, and trospium. They reduce urgency and frequency, but because the same chemical signal operates throughout the body, side effects like dry mouth, constipation, and blurred vision are common.
Beta-3 agonists take the opposite approach. Instead of blocking the “squeeze” signal, they activate a receptor that relaxes the bladder muscle during filling. Mirabegron was the first in this class, followed by vibegron. They tend to cause fewer of the classic dry-mouth and constipation problems associated with antimuscarinics.
How Side Effects Compare Across Medications
Dry mouth is the most frequent reason people stop taking bladder medications, so the differences here matter. In clinical trials, dry mouth rates varied widely depending on the drug and formulation:
- Oxybutynin (oral): Among the highest dry mouth rates of any bladder drug. A transdermal patch version drops the rate to about 7%, nearly the same as a placebo, because it bypasses the liver processing that creates the problematic byproduct.
- Tolterodine: 23% with the extended-release version, 30% with immediate-release.
- Solifenacin: About 11% at the lower dose, rising to 28% at the higher dose.
- Darifenacin: 20% at the lower dose, 36% at the higher dose.
- Trospium (extended-release): About 11%, which compares favorably to the 20% seen with the older twice-daily version.
Beta-3 agonists largely sidestep these issues. Mirabegron’s prescribing information does carry a warning about blood pressure increases, and periodic monitoring is recommended. Vibegron, the newer option, shows no measurable activity at the heart-related receptor subtypes that can raise blood pressure. An ambulatory blood pressure study found vibegron had no significant effect on blood pressure or heart rate, even in people with pre-existing controlled hypertension.
The Dementia Concern With Anticholinergics
A large English study published in 2024 tracked over 170,000 people aged 55 and older who were diagnosed with dementia and compared their prior medication use against more than 800,000 matched controls without dementia. The overall adjusted odds of dementia were 18% higher among people who had used anticholinergic bladder drugs in the 3 to 16 years before diagnosis.
Not all drugs carried the same risk. Oxybutynin showed the strongest association, with a 31% increase in dementia odds at moderate cumulative use. Tolterodine and solifenacin also showed significantly elevated risk. Importantly, darifenacin, trospium, and fesoterodine were not linked to a significant increase. Mirabegron, which is not an anticholinergic, showed no clear independent association either.
This doesn’t prove these drugs cause dementia, but the pattern is consistent enough that many clinicians now prefer beta-3 agonists or the lower-risk anticholinergics for older adults. If you’re over 55 and considering a bladder medication you’ll use long term, this is worth discussing.
Beta-3 Agonists: Mirabegron vs. Vibegron
Both mirabegron and vibegron relax the bladder muscle through the same receptor, but they aren’t identical. Vibegron has higher selectivity for the target receptor and essentially no activity at the beta-1 receptors in the heart, which gives it a cleaner cardiovascular profile. In network meta-analyses, the two drugs show similar effectiveness for reducing urgency, frequency, and incontinence episodes.
Combination therapy is also an option. Low-dose mirabegron combined with low-dose solifenacin has been shown in three large randomized trials to significantly improve urgency and incontinence beyond what either drug achieves alone. This combination can allow lower doses of the anticholinergic component, reducing side effects while boosting effectiveness.
How Quickly Medications Work
Most bladder medications begin producing noticeable effects within the first week. However, maximum benefit often takes longer to assess, and many clinical trials measure outcomes at 4 to 12 weeks. If you’ve been on a medication for a few weeks without improvement, your prescriber may adjust the dose or switch to a different option rather than waiting indefinitely.
Vaginal Estrogen for Postmenopausal Women
For postmenopausal women, low-dose vaginal estrogen cream is a well-supported option that works through a completely different pathway than the standard bladder drugs. Declining estrogen levels after menopause thin the tissues of the bladder and urethra, contributing to urgency and leaking. Applying a small amount of estrogen cream twice weekly for 12 weeks has been shown to increase beneficial bacteria in the bladder itself, and this change correlates with modest improvements in urgency incontinence symptoms.
Vaginal estrogen is considered a first-line option alongside behavioral changes for postmenopausal women with overactive bladder symptoms. It can be used alone or combined with other bladder medications.
Stress Incontinence Is a Different Problem
If your leaking happens mainly when you cough, sneeze, laugh, or exercise, that’s stress incontinence, and the medication landscape looks very different. In the United States, no medication is FDA-approved for stress incontinence. Duloxetine, a drug that increases nerve signals to the urethral muscle, is approved for this use in Europe but not in the U.S., partly due to concerns that the risks may outweigh the benefits. Pelvic floor exercises and surgical options remain the primary treatments for stress incontinence.
When Medications Aren’t Enough
The American Urological Association’s 2024 guidelines note that treatment doesn’t have to follow a rigid stepwise progression. Behavioral therapy, including bladder training and timed voiding, is recommended for everyone with overactive bladder. Medications can be started alongside those strategies rather than only after behavioral approaches fail.
For people who don’t get adequate relief from medications or can’t tolerate the side effects, minimally invasive procedures are effective alternatives. Bladder injections of botulinum toxin are among the most studied: in a 15-year follow-up of women with urgency incontinence, 74.5% achieved complete pad-free status after treatment. The effects of each injection last an average of about 6 months based on clinical trials, though the real-world interval between injections averages around 18 months, partly due to scheduling and patient preference. About 60% of patients eventually need additional injections.
Other options at this stage include sacral neuromodulation, a small implanted device that regulates nerve signals to the bladder, and percutaneous tibial nerve stimulation, a less invasive office procedure that works through a nerve near the ankle.